Breaking News

Amgen to Acquire Five Prime Therapeutics for $1.9B

Adds Five Prime's pipeline of immuno-oncology and targeted cancer therapies to Amgen's oncology portfolio.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen entered an agreement to acquire Five Prime Therapeutics for approximately $1.9 billion in cash. This acquisition adds Five Prime’s innovative pipeline of immuno-oncology and targeted cancer therapies to Amgen’s oncology portfolio.   Five Prime’s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer. Bemarituzumab targets FGFR2b, whic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters